Sarepta Therapeutics 향후 성장

Future 기준 점검 3/6

Sarepta Therapeutics 의 수익은 연간 9.5% 감소할 것으로 예상되는 반면, 연간 수익은 50.4% 로 증가할 것으로 예상됩니다. EPS는 연간 51.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 6.1% 로 예상됩니다.

핵심 정보

50.4%

이익 성장률

51.06%

EPS 성장률

Biotechs 이익 성장	22.8%
매출 성장률	-9.5%
향후 자기자본이익률	6.09%
애널리스트 커버리지	Good
마지막 업데이트	07 Apr 2026

최근 향후 성장 업데이트

Recent updates

Sarepta Therapeutics: A $2B Business Priced Like It's Broken

Mar 24

There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise

Dec 04

Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 32% But Its Business Still Trails The Industry

Oct 18

We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right

May 29

The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot

May 08

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 20

Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty

Mar 18

Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Low P/S No Reason For Excitement

Mar 05

Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness

Mar 04

These 4 Measures Indicate That Sarepta Therapeutics (NASDAQ:SRPT) Is Using Debt Reasonably Well

Jan 22

Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely

Jan 16

Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 13

이익 및 매출 성장 예측

NasdaqGS:SRPT - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	1,439	94	587	463	13
12/31/2027	1,439	83	630	548	19
12/31/2026	1,737	327	353	490	20
12/31/2025	2,198	-713	-315	-205	N/A
9/30/2025	2,414	-272	-389	-245	N/A
6/30/2025	2,482	-58	-454	-301	N/A
3/31/2025	2,233	-248	-698	-547	N/A
12/31/2024	1,902	235	-353	-206	N/A
9/30/2024	1,640	122	-480	-352	N/A
6/30/2024	1,505	47	-528	-396	N/A
3/31/2024	1,403	17	-552	-534	N/A
12/31/2023	1,243	-536	-486	-501	N/A
9/30/2023	1,105	-691	-513	-539	N/A
6/30/2023	1,003	-908	-432	-489	N/A
3/31/2023	976	-1,115	-470	-434	N/A
12/31/2022	933	-703	-358	-325	N/A
9/30/2022	876	-716	-289	-262	N/A
6/30/2022	835	-507	-348	-322	N/A
3/31/2022	766	-357	-285	-364	N/A
12/31/2021	702	-419	-382	-443	N/A
9/30/2021	646	-486	-551	-588	N/A
6/30/2021	600	-634	-681	-702	N/A
3/31/2021	573	-704	-795	-701	N/A
12/31/2020	540	-554	133	107	N/A
9/30/2020	495	-601	155	118	N/A
6/30/2020	450	-530	342	289	N/A
3/31/2020	407	-656	373	318	N/A
12/31/2019	381	-715	-516	-456	N/A
9/30/2019	365	-620	N/A	-415	N/A
6/30/2019	345	-570	N/A	-461	N/A
3/31/2019	323	-403	N/A	-499	N/A
12/31/2018	301	-362	N/A	-389	N/A
9/30/2018	274	-245	N/A	-297	N/A
6/30/2018	241	-216	N/A	-242	N/A
3/31/2018	203	-170	N/A	-210	N/A
12/31/2017	155	-51	N/A	-232	N/A
9/30/2017	103	-115	N/A	-282	N/A
6/30/2017	57	-124	N/A	-285	N/A
3/31/2017	22	-123	N/A	-243	N/A
12/31/2016	5	-267	N/A	-246	N/A
9/30/2016	1	-243	N/A	-196	N/A
6/30/2016	1	-239	N/A	-182	N/A
3/31/2016	1	-218	N/A	-167	N/A
12/31/2015	1	-220	N/A	-149	N/A
9/30/2015	0	-200	N/A	-144	N/A
6/30/2015	1	-177	N/A	-133	N/A

애널리스트 향후 성장 전망

수입 대 저축률: SRPT 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.4%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: SRPT (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: SRPT 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: SRPT 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -9.5%).

고성장 매출: SRPT 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -9.5%).

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: SRPT의 자본 수익률은 3년 후 6.1%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/04/10 12:35
종가	2026/04/10 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Sarepta Therapeutics, Inc.는 48명의 분석가가 다루고 있습니다. 이 중 20명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Brian Skorney	Baird
Huidong Wang	Barclays
Eliana Merle	Barclays

Sarepta Therapeutics 향후 성장

Future 기준 점검 3/6

핵심 정보

최근 향후 성장 업데이트

Price target decreased by 8.8% to US$21.41

Price target decreased by 7.1% to US$21.82

Consensus EPS estimates fall by 51%

Price target decreased by 25% to US$72.61

Sarepta Therapeutics, Inc. Revises Earnings Guidance for 2025

Consensus EPS estimates fall by 13%

Recent updates

New minor risk - Share price stability

Sarepta Therapeutics Announces First Clinical Data from Sirna Pipeline Targeting FSHD1 and DM1

Sarepta Therapeutics: A $2B Business Priced Like It's Broken

Sarepta Therapeutics Provides Regulatory Update On Amondys 45 And Vyondys 53

Sarepta Announces That Screening and Enrollment Are Underway in Endeavor Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of Elevidys Gene Therapy for Non-Ambulant Individuals with Duchenne

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Douglas Ingram Plans to Retire as Chief Executive Officer of Sarepta Therapeutics, Inc

Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in Japan

Sarepta Therapeutics, Inc. to Report Q4, 2025 Results on Feb 25, 2026

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

Sarepta Therapeutics, Inc. Announces Positive Topline Three-Year EMBARK Results Showing EleVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Sarepta Therapeutics, Inc. Announces Submission of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

President & COO recently sold US$294k worth of stock

President & COO notifies of intention to sell stock

There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise

Sarepta Therapeutics, Inc. Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of Elevidys Gene Therapy for Non-Ambulant Individuals with Duchenne

Sarepta Provides Progress Update for Srp-1003, Its Investigational Sirna Treatment for Myotonic Dystrophy Type 1

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Price target decreased by 8.8% to US$21.41

Price target decreased by 7.1% to US$21.82

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Sarepta Therapeutics Announces Completion of Its Confirmatory Study, ESSENCE

Sarepta Therapeutics, Inc. to Report Q3, 2025 Results on Nov 03, 2025

Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 32% But Its Business Still Trails The Industry

Sarepta Therapeutics, Inc. announced that it expects to receive $20 million in funding from J. Wood Capital Advisors LLC

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm

Sarepta Therapeutics, Inc. to Report Q2, 2025 Results on Aug 06, 2025

FDA Informs Sarepta Therapeutics, Inc. to Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals with Duchenne Muscular Dystrophy

Sarepta Therapeutics Acknowledges CHMP Negative Opinion for Eletidys in the European Union

Sarepta Therapeutics, Inc. Announces Voluntary Pause of Eletidys Shipments in the U.S

Sarepta Therapeutics, Inc Announces Workforce Reduction Due to Strategic Restructuring

Consensus EPS estimates fall by 51%

New major risk - Share price stability

Price target decreased by 25% to US$72.61

U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta's Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4

We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right

Sarepta Therapeutics, Inc. Provides Update on UK Dosing in ENVISION Study of Eletidys for the Treatment of Duchenne Muscular Dystrophy

New major risk - Financial position

Sarepta Therapeutics, Inc. Shares New Protein Expression and Safety Results from Endeavor in Participants 2 Years Old At Time of Treatment

Sarepta Therapeutics, Inc. Announces Approval in Japan of ELEVIDYS, A Gene Therapy to Treat Duchenne Muscular Dystrophy

The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Sarepta Therapeutics, Inc. Revises Earnings Guidance for 2025

Investor sentiment deteriorates as stock falls 23%

Sarepta Therapeutics, Inc., Annual General Meeting, Jun 05, 2025

Sarepta Therapeutics, Inc. to Report Q1, 2025 Results on May 06, 2025

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27%

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

New minor risk - Share price stability

Sarepta Therapeutics, Inc. Provides Update on ELEVIDYS

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 13%

Investor sentiment deteriorates as stock falls 27%

Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty

Executive VP & Chief Customer Officer exercised options and sold US$950k worth of stock

Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Low P/S No Reason For Excitement

Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2025

Sarepta Therapeutics, Inc. to Report Q4, 2024 Results on Feb 26, 2025

Sarepta Therapeutics, Inc. Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS

Consensus EPS estimates increase by 11%

These 4 Measures Indicate That Sarepta Therapeutics (NASDAQ:SRPT) Is Using Debt Reasonably Well

Consensus EPS estimates increase by 10%

Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely

Sarepta Therapeutics, Inc. Reiterates Earnings Guidance for the Full Year 2025

Sarepta Therapeutics, Inc. Completes Enrollment in EMERGENE, Phase 3 Clinical Study of SRP-9003 for Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Board Member notifies of intention to sell stock

New minor risk - Insider selling